Avalo Therapeutics, Inc. (AVTX) stock forecast and price target
Price $7.76 · data as of November 13, 2026
12-month price target
Average target$34.80
Upside / downside+348.5%
Analysts10
ConsensusStrong buy
Low $10.00Average $34.80High $60.00
Gold marker: average target · white marker: today’s price ($7.76)
Analyst ratings
Strong buy 2Buy 10Hold 2Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-2.35 | +59.8% | $0 |
| Next fiscal year ends December 31, 2027 | $-2.62 | −11.4% | $0 |
| Next quarter ends December 31, 2026 | $-0.47 | −27.7% | $0 |
| Quarter after ends March 31, 2027 | $-0.62 | +36.7% | $0 |
Consensus of the analysts covering Avalo Therapeutics, updated daily. In the last 30 days 3 estimates were raised and 0 lowered.
Frequently asked questions
What is the Avalo Therapeutics stock price target?
The average 12-month target from 10 analysts is $34.80, 348.5% above the current price of $7.76 Targets range from $10.00 to $60.00.
Is Avalo Therapeutics a buy according to analysts?
The consensus rating is “Strong buy” (2 strong buy, 10 buy, 2 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is Avalo Therapeutics expected to earn?
Analysts expect EPS of $-2.35 for the fiscal year ending December 31, 2026 and $-2.62 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.